Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Transthyretin Amyloid Cardiomyopathy: A Propensity-Matched Cohort Study
{{output}}
Background and objectives: The evidence for sodium-glucose cotransporter-2 inhibitors (SGLT2i) in heart failure (HF) secondary to transthyretin amyloid cardiomyopathy (ATTR-CM) is limited. Evaluate the impact of SGLT2i on clinica... ...
